HC Wainwright Reiterates “Buy” Rating for OKYO Pharma (NASDAQ:OKYO)

HC Wainwright reiterated their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a research report report published on Tuesday morning,Benzinga reports. They currently have a $7.00 target price on the stock.

OKYO Pharma Stock Down 0.9 %

NASDAQ OKYO opened at $1.09 on Tuesday. OKYO Pharma has a fifty-two week low of $0.81 and a fifty-two week high of $1.90. The firm’s fifty day moving average price is $1.09 and its two-hundred day moving average price is $1.07.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.